Adenomatous Polyps, Hyperplastic Polyps
Conditions
Brief summary
The purpose of this prospective, non-interventional study is to validate the Narrow Band Imaging International Colorectal Endoscopic (NICE) classification for differentiating subcentimetric hyperplastic and adenomatous polyps by using Fuji Intelligent Color Enhancement (FICE) technology with high-definition without optical magnification.
Detailed description
1. In order to create a video-library of endoscopic cases, patients undergoing screening or diagnostic colonoscopy will be considered for inclusion. Patients with at least one histologically verified \<10 mm polyp will be included. A short video-clip (around 15-20 seconds) of each polyp both at white-light and FICE-light will be recorded and stored in an anonymized database. 2. Once the video-library is completed, each of 7 experts will independently review all the cases. For each case, any observer will assess each of the three NICE criteria (colour/vascularization/surface), the degree of confidence (low/high), and classify the lesion as neoplastic or non-neoplastic. The primary outcomes are the accuracy of FICE technology with high-definition and without magnification, when adopting NICE classification, to differentiate between hyperplastic and adenomatous lesions, and the inter-observer agreement in such differentiation. Secondary end-points are to assess at multivariate measure the role of any individual criteria of NICE classification in the discrimination between the two histotypes, and possible adaptations of NICE classification in order to be applied with FICE.
Interventions
PROCEDUREvirtual chromo-endoscopy using FICE Fujifilm Technology
For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
Sponsors
Universitaire Ziekenhuizen KU Leuven
Royal Alexandra Hospital
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Nuovo Regina Margherita Hospital
University of Erlangen-Nürnberg Medical School
University Hospital Regensburg
Hôpital Edouard Herriot
Istituto Clinico Humanitas
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
1. The patient is undergoing colonoscopy for screening, for surveillance in follow-up of previous polypectomy or for diagnostic work-up; 2. The patient is at satisfactory risk to undergo abdominal surgery; 3. The patient must understand and provide written consent for the procedure.
Exclusion criteria
1. Patients with inflammatory bowel disease; 2. Patients with a personal history of polyposis syndrome; 3. Patients with diverticulitis or toxic megacolon; 4. Patients with a history of radiation therapy to abdomen or pelvis. 5. Patients with a history of severe cardiovascular, pulmonary, liver or renal disease; 6. Personal history of coagulation disorders or use of anticoagulants 7. Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| accuracy of the NICE criteria using FICE technology for differentiating between the non-neoplastic and neoplastic histotypes in diagnoses with high-confidence on a video-library of 110 polyps reviewed by 7 experts. | up to 6 months | 7 experts will review videos from a video-library of subcentimetric polyps removed and histologically verified and will assess each of the three NICE criteria (colour/vascularization/surface), and classify the lesion as neoplastic or non-neoplastic with low or high confidence. |
| Inter-observer agreement among the 7 experts | up to 6 months | The inter-observer agreement, among the 7 experts, on the final diagnosis (neoplastic or non-neoplastic) and on each individual NICE criterion for each polyp will be determined by using K statistics . |
Other
| Measure | Time frame |
|---|---|
| Accuracy of additional criteria, such as the presence of mucus, to differentiate between sub-types of non-neoplastic lesions (i.e. serrated lesions) | up to 6 month |
Countries
Belgium, France, Germany, Italy, United Kingdom
Contacts
Primary ContactAlessandro Repici, MD
Outcome results
None listed